查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1169169

先天性高胰岛素血症治疗市场：按疾病类型、药物类型（二氮秦,奥曲□,胰高血糖素,硝苯地平等）,给药途径,分销渠道,地区-规模,份额,展望,机会分析2022-2030

Congenital Hyperinsulinism Treatment Market, by Disease Type, Drug Type (Diazoxide, Octreotide, Glucagon, Nifedipine, Other, Route of Administration, Distribution Channel, & Region - Size, Share, Outlook, & Opportunity Analysis, 2022 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 190 Pages | 商品交期: 2-3个工作天内

价格
简介目录

先天性高胰岛素血症 (CHI)，也称为高胰岛素血症性低血糖症，是一种罕见的内分泌疾病，主要影响新生儿、婴儿和儿童，并导致脑损伤和严重低血糖症。是最常见的原因 胰腺BETA细胞胰岛素分泌过多导致KATP通道基因发生基因突变（ABCC8、KCNJ11、HNF4A、HNF1A、HADH、UCP2或GLUD1、GCK、SLC16A1的激活突变），导致先天性超敏反应。据说会引起胰岛素血症. 由于对大脑造成永久性损伤的风险很高，CHI 需要及时诊断和立即治疗，以预防癫痫、脑瘫和神经发育障碍等并发症。 根据国家罕见疾病组织数据库，在大多数患有 HI 的国家中，每 25,000 人中就有 1 人到 50,000 人中有 1 人会在出生后的头几个月出现低血糖症。 低血糖可引起多种症状，从烦躁、嗜睡、过度饥饿和心率加快等常见症状到癫痫发作和昏迷等更严重的症状。 有些是短暂的，有些是由于遗传缺陷而终生的，并且根据疾病的形式有不同的原因。 在早产儿中，过多的胰岛素会导致低血糖。 胰岛素分泌不足的原因尚不清楚，但可持续数天至数月。

市场动态

包括 Zealand Pharma A/S、Hanmi Pharm.Co.、Eli Lilly and Company 在内的多家主要参与者正在为治疗先天性高胰岛素血症的新型治疗方案的开发进行持续研究，预计这将推动期间全球先天性高胰岛素血症药物市场。 例如，2019 年 5 月，生物技术公司 Zealand Pharma A/S 启动了 Dasiglucagon 的 3 期临床试验。 该试验旨在评估 dasiglucagon 治疗先天性高胰岛素血症儿科患者的疗效和安全性。 该研究预计将于 2022 年 12 月完成。 Dasiglucagon 是胰高血糖素的□类似物，设计有七个氨基酸取代以消除原纤维形成和□聚集。

这项研究的主要特点

  • 本报告对全球先天性高胰岛素血症药物市场进行了深入分析，揭示了以 2021 年为基准年的预测期（2022-2030 年）的市场规模和復合年增长率 (CAGR%))。
  • 解释了不同细分市场的潜在创收机会，并描述了针对该市场的有吸引力的投资建议矩阵。
  • 它还提供重要的见解，例如市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争战略。
  • 根据以下参数对全球先天性高胰岛素血症治疗市场的主要参与者进行了介绍 - 公司亮点、产品组合、主要亮点、财务业绩和战略。
  • 本研究涵盖的主要公司包括 Zealand Pharma A/S、Eli Lilly and Company、Xeris Pharmaceuticals, Inc.、Rezolute, Inc.、Hanmi Pharm.Co., Ltd.、Fresenius Kabi AG 和 Eiger BioPharmaceuticals。 , Crinetics Pharmaceuticals, Inc., AmideBio, LLC, Jolly Healthcare, e5 Pharma, LLC, Merck & Co., Inc., Novo Nordisk A/S, Amphaster Pharmaceuticals, Inc., USV Private Limited, Teva Pharmaceutical Industries Ltd.
  • 这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
  • 《全球先天性高胰岛素血症治疗市场》报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
  • 利益相关者可以通过用于分析全球先天性高胰岛素血症治疗市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

  • 调查目的
  • 先决条件
  • 缩写说明

第2章市场展望

  • 报告内容
    • 市场定义和范围
  • 执行摘要
    • 按疾病类型划分的市场概况
    • 市场概况：按药物类型
    • 按给药途径划分的市场概况
    • 市场概况：按销售渠道
    • 市场概况：按地区
  • 连贯机会图 (COM)

第 3 章市场动态、法规和趋势分析

  • 市场动态
    • 司机
    • 约束因素
    • 市场机会
  • 影响分析
  • 市场趋势
  • 近期趋势
  • 收购和合作场景
  • 监管场景
  • 定价分析
  • 害虫分析

第 4 章先天性高胰岛素血症药物的全球市场：按疾病类型分类，2017-2030 年。

  • KATP-HI
  • 广东粤海
  • GK-HI
  • 其他（SCHAD HI、HNF4A/HNF1A HI 等）

第 5 章先天性高胰岛素血症药物的全球市场：按药物类型分列，2017-2030

  • 二氮秦
  • 奥曲□
  • 胰高血糖素
  • 硝苯地平
  • 其他（西罗莫司、氯塞秦等）

第 6 章先天性高胰岛素血症药物的全球市场：按给药途径，2017-2030

  • 口语
  • 肠外

第 7 章先天性高胰岛素血症药物的全球市场：按分销渠道，2017-2030

  • 医院药房
  • 零售药房
  • 在线药店

第 8 章先天性高胰岛素血症药物的全球市场：按地区划分，2017-2030

  • 北美
  • 美国
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲地区
  • 欧洲
  • 英国
  • 德国
  • 意大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 东盟
  • 澳大利亚
  • 韩国
  • 其他亚太地区
  • 中东
  • 海湾合作委员会
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中非
  • 南非

第9章竞争格局

  • Zealand Pharma A/S
  • Eli Lilly and Company
  • Xeris Pharmaceuticals, Inc.
  • Rezolute, Inc.
  • Hanmi Pharm.Co., Ltd.
  • Fresenius Kabi AG
  • Eiger BioPharmaceuticals.
  • Crinetics Pharmaceuticals, Inc.
  • AmideBio,LLC
  • Jolly Healthcare
  • e5 Pharma, LLC.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Amphastar Pharmaceuticals.Inc,
  • USV Private Limited.
  • Teva Pharmaceutical Industries Ltd.

第10章 章节

  • 调查手法
  • 关于出版社
简介目录
Product Code: CMI5329

Congenital hyperinsulinism(CHI) also called as hyperinsulinemic hypoglycemia, a rare endocrine condition that causes low blood glucose levels and occurs mainly in newborn babies, infants and children leading to permanent brain injury and is most frequent cause of severe hypoglycemia. Over secretion of insulin by beta cells in pancreas leads to gene mutation in KATP channel genes (ABCC8 and KCNJ11, HNF4A, HNF1A, HADH, and UCP2 or activating mutations of GLUD1, GCK, and SLC16A1) that cause congenital hyperinsulinism. There is significant risk of permanent brain damage in CHI, hence it is necessary to make a prompt diagnosis and obtain immediate management of the disease to prevent complications such as epilepsy, cerebral palsy and neurodevelopmental deficits. According to the National Organization for Rare Disorders database, approximately 1/25,000 to 1/50,000 HI births occurs in most of the countries including HI develop hypoglycemia during the first month of life. Irritability, sleepiness, excessive hunger, rapid heart rate are common symptoms that occurs while more severe symptoms, such as seizures and coma occur. There are many causes of congential hyperinsulinism based on different forms of the disease for example there are transient forms while some are due to genetic defects and persist for life. Prematurely born babies sometimes, develop hypoglycemia due to excessive insulin secretion. The cause of this inappropriate insulin secretion is still not clear, but it can last a few days to months.

Market Dynamics

Ongoing research for development of novel therapeutic options for the treatment of congenital hyperinsulinismby various key players such as Zealand Pharma A/S, Hanmi Pharm.Co., Ltd., Eli Lilly and Company is anticipated to drive the growth of global congenital hyperinsulinismtreatment market over the forecast period. For instance, in May 2019, Zealand Pharma A/S, a biotechnology company initiated Phase 3 clinical trial of Dasiglucagon. The study aims to assess the efficacy and safety of Dasiglucagon for the treatment of pediatric patients with congenital hyperinsulinism. The study is estimated to be completed by December 2022. Dasiglucagon is a peptide analogue of glucagon consisting 7 amino acid substitutions engineered to eliminate fibril formation as well as peptide aggregation.

Key features of the study:

  • This report provides an in-depth analysis of the global congenital hyperinsulinism treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global congenital hyperinsulinism treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study are Zealand Pharma A/S, Eli Lilly and Company, Xeris Pharmaceuticals, Inc., Rezolute, Inc., Hanmi Pharm.Co., Ltd., Fresenius Kabi AG, Eiger BioPharmaceuticals., Crinetics Pharmaceuticals, Inc., AmideBio, LLC, Jolly Healthcare, e5 Pharma,LLC, Merck & Co.,Inc., Novo Nordisk A/S, Amphaster Pharmaceuticals,Inc., USV Private Limited, Teva Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global congenital hyperinsulinism treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global congenital hyperinsulinism treatment market

Detailed Segmentation:

  • Global Congenital Hyperinsulinism Treatment Market, By Disease Type:
    • KATP-HI
    • GDH-HI
    • GK-HI
    • Other (SCHAD HI, HNF4A/HNF1A, etc.)
  • Global Congenital Hyperinsulinism Treatment Market, By Drug Type:
    • Diazoxide
    • Octerotide
    • Glucagon
    • Nifedipine
    • Other (Sirolimus, Chlorothiazide, etc.)
  • Global Congenital Hyperinsulinism Treatment Market, By Route of Administration:
    • Oral
    • Parental
  • Global Congenital Hyperinsulinism Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Congenital Hyperinsulinism Treatment Market, By Region:
    • North America
      • By Country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Region/Country
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Hanmi Pharm.Co., Ltd.,
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Zealand Pharma A/S
    • Eli Lilly and Company
    • Xeris Pharmaceuticals, Inc.,
    • Rezolute, Inc.,
    • Fresenius Kabi AG
    • Eiger BioPharmaceuticals.,
    • Crinetics Pharmaceuticals, Inc.,
    • AmideBio,LLC
    • Jolly Healthcare
    • e5 Pharma,LLC
    • Merck & Co., Inc.
    • Novo Nordisk A/S
    • Amphaster Pharmaceuticals, Inc.
    • USV Private Limited
    • Teva Pharmaceutical Industries

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Disease Type
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Recent Developments
  • Acquisitions and Partnerships Scenario
  • Regulatory Scenario
  • Pricing Analysis
  • PEST Analysis

4. Global Congenital Hyperinsulinism Treatment Market, By Disease Type, 2017-2030,(US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • KATP-HI
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • GDH-HI
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • GK-HI
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Other (SCHAD HI, HNF4A/HNF1A HI, etc.)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

5. Global Congenital Hyperinsulinism Treatment Market, By Drug Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Diazoxide
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Octreotide
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Glucagon
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Nifedipine
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Other (Sirolimus, Chlorothiazide, etc.)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Congenital Hyperinsulinism Treatment Market, By Route of Administration, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Parenteral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Congenital Hyperinsulinism Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Congenital Hyperinsulinism Treatment Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • UK
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Zealand Pharma A/S
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eli Lilly and Company
  • Xeris Pharmaceuticals, Inc.
  • Rezolute, Inc.
  • Hanmi Pharm.Co., Ltd.
  • Fresenius Kabi AG
  • Eiger BioPharmaceuticals.
  • Crinetics Pharmaceuticals, Inc.
  • AmideBio,LLC
  • Jolly Healthcare
  • e5 Pharma, LLC.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Amphastar Pharmaceuticals.Inc,
  • USV Private Limited.
  • Teva Pharmaceutical Industries Ltd.

10. Section

  • Research Methodology
  • About Us